92
Participants
Start Date
August 9, 2010
Primary Completion Date
July 1, 2011
Study Completion Date
June 1, 2016
GSK2118436
Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
GSK Investigational Site, Westmead
GSK Investigational Site, Newcastle
GSK Investigational Site, Nedlands
GSK Investigational Site, Berlin
GSK Investigational Site, Marseille
GSK Investigational Site, Genoa
GSK Investigational Site, Philadelphia
GSK Investigational Site, Lübeck
GSK Investigational Site, Kiel
GSK Investigational Site, Bordeaux
GSK Investigational Site, Montpellier
GSK Investigational Site, Padua
GSK Investigational Site, Nashville
GSK Investigational Site, Essen
GSK Investigational Site, Lille
GSK Investigational Site, Paris
GSK Investigational Site, Napoli
GSK Investigational Site, Los Angeles
GSK Investigational Site, Los Angeles
GSK Investigational Site, Boulogne-Billancourt
GSK Investigational Site, San Francisco
GSK Investigational Site, Villejuif
GSK Investigational Site, Houston
Lead Sponsor
GlaxoSmithKline
INDUSTRY